Skip to main content
PYPD
NASDAQ Industrial Applications And Services

PolyPid Posts Q3 Loss of $0.24/Share; Cash to Fund Operations Into 2028 Ahead of Nov 28 PDUFA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$6.97
Mkt Cap
$134.058M
52W Low
$3.5
52W High
$7.15
52W Position info
99% above low
Off High info
2.5% below high
Rel. Volume info
3.5× avg
Market data snapshot near publication time

PYPD sits 99% above its 52-week low of $3.5 on elevated volume (3.5× avg).

Summary

PolyPid reported a Q3 2026 net loss of $5.8 million ($0.24 per share) and said its $15.5 million cash balance plus a post-quarter $15 million Azurity milestone funds operations into 2028, three weeks before the November 28 D-PLEX100 PDUFA date.


Key Events · Earnings and Guidance · PYPD

  • Q3 Loss Narrows to $0.24/Share

    Net loss of $5.8 million, or $(0.24) per share, versus $(0.37) in Q3 2025; the nine-month loss was $21.3 million, or $(0.94) per share.

  • Cash Runway Extended Into 2028

    Cash, cash equivalents and short-term deposits of $15.5 million at September 30, 2026, plus a $15 million Azurity milestone received after quarter end; management says this funds operations into 2028.

  • Azurity Deal Delivers $30M So Far

    $15 million on signing in July 2026 plus $15 million on FDA NDA acceptance, with over $290 million in remaining regulatory, launch and sales milestones plus mid-teen to mid-twenties royalties.

  • PDUFA Decision Due November 28, 2026

    D-PLEX100 NDA is under FDA Priority Review with a November 28, 2026 goal date; labeling talks are underway and a U.S. launch by Azurity is targeted for early 2027.


Analysis · PYPD · Industrial Applications And Services

With the November 28, 2026 PDUFA goal date for D-PLEX100 just three weeks away, the runway this quarter buys matters more than the loss itself. Cash and short-term deposits stood at $15.5 million on September 30, and a $15 million Azurity milestone landed after the quarter closed; management now says that plus expected partner proceeds funds operations into 2028, clearing any near-term financing overhang as the binary FDA decision approaches. The quarter produced a $5.8 million net loss, or $0.24 per share, versus $0.37 a year ago, aided by $2.5 million of other income from recognizing deferred revenue after the ADVANZ termination. Per-share figures also rest on a larger base, with the share count up to 21.1 million from 18.2 million at year-end 2025.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PYPD was trading at $6.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $134.1M. The 52-week trading range was $3.50 to $7.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PYPD - Latest Insights

PYPD
Nov 11, 2026, 9:31 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $6.22
Real-time Price: $6.97 info
Change: +$0.7509 (+12%) info
Market Cap: $134.058M info
PYPD
Oct 28, 2026, 8:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.75
Real-time Price: $6.97 info
Change: +$1.22 (+21%) info
Market Cap: $134.058M info
PYPD
Oct 01, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.30
Real-time Price: $6.97 info
Change: +$1.67 (+32%) info
Market Cap: $134.058M info
PYPD
Oct 01, 2026, 8:56 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.27
Real-time Price: $6.97 info
Change: +$1.70 (+32%) info
Market Cap: $134.058M info
PYPD
Aug 12, 2026, 4:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.80
Real-time Price: $6.97 info
Change: +$2.17 (+45%) info
Market Cap: $134.058M info